Alterity Therapeutics (ATHE) Competitors $1.05 -0.07 (-6.25%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends ATHE vs. KALA, RNXT, SRZN, MRKR, PLUR, DRRX, INKT, DARE, NAII, and LGVNShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include KALA BIO (KALA), RenovoRx (RNXT), Surrozen (SRZN), Marker Therapeutics (MRKR), Pluri (PLUR), DURECT (DRRX), MiNK Therapeutics (INKT), Daré Bioscience (DARE), Natural Alternatives International (NAII), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. KALA BIO RenovoRx Surrozen Marker Therapeutics Pluri DURECT MiNK Therapeutics Daré Bioscience Natural Alternatives International Longeveron Alterity Therapeutics (NASDAQ:ATHE) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Which has more volatility & risk, ATHE or KALA? Alterity Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.13, meaning that its stock price is 313% less volatile than the S&P 500. Is ATHE or KALA more profitable? Alterity Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A KALA BIO N/A -448.61%-69.37% Does the MarketBeat Community favor ATHE or KALA? KALA BIO received 297 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 66.82% of users gave KALA BIO an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes360.00% Underperform Votes240.00% KALA BIOOutperform Votes30066.82% Underperform Votes14933.18% Do analysts rate ATHE or KALA? Alterity Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 280.95%. KALA BIO has a consensus price target of $15.00, suggesting a potential upside of 133.28%. Given Alterity Therapeutics' higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ATHE or KALA? In the previous week, KALA BIO had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for KALA BIO and 2 mentions for Alterity Therapeutics. KALA BIO's average media sentiment score of 0.57 beat Alterity Therapeutics' score of 0.21 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, ATHE or KALA? Alterity Therapeutics has higher earnings, but lower revenue than KALA BIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AKALA BIO$3.89M7.62-$42.20M-$12.47-0.52 Do insiders and institutionals believe in ATHE or KALA? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 8.3% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryKALA BIO beats Alterity Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Resource Stock DigestThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best names in the lithium space will be set for escalating gains in 2025 and beyond. It’s all being driven by the global EV boom as millions of drivers ditch their gasoline-chugging cars and trucks in favor of lithium-ion-powered vehicles in record numbers. Everything you need to know is in our FREE online lithium report you can get here. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.67M$6.40B$5.00B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E RatioN/A10.02130.6617.50Price / SalesN/A318.991,201.6989.08Price / CashN/A22.1633.4132.51Price / Book0.855.454.684.68Net Income-$12.54M$152.73M$118.04M$225.43M7 Day Performance-11.02%-4.36%-2.44%-2.04%1 Month Performance-16.67%-8.68%-4.03%0.04%1 Year PerformanceN/A28.52%29.54%24.47% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics3.1703 of 5 stars$1.05-6.3%$4.00+281.0%-52.9%$7.67MN/A0.0010News CoverageKALAKALA BIO4.2156 of 5 stars$6.43-0.6%$15.00+133.3%+18.7%$29.64M$3.89M-0.4830RNXTRenovoRx2.6523 of 5 stars$1.21+9.0%$6.13+406.2%+85.0%$29.04MN/A-2.166News CoveragePositive NewsGap UpHigh Trading VolumeSRZNSurrozen2.9667 of 5 stars$8.90-12.4%N/A+47.2%$28.93M$10M0.0042Positive NewsGap DownHigh Trading VolumeMRKRMarker Therapeutics3.8695 of 5 stars$3.18-0.3%$19.00+497.5%+11.9%$28.37M$3.31M0.0060PLURPluri0.1625 of 5 stars$5.06+0.2%N/A+4.9%$28.13M$598,000.00-0.84150DRRXDURECT3.1142 of 5 stars$0.90-8.1%$5.00+453.3%+59.9%$28.05M$8.55M-1.4480Analyst ForecastAnalyst RevisionNews CoverageINKTMiNK Therapeutics2.904 of 5 stars$0.70+2.6%$6.50+822.1%-33.0%$27.88MN/A-1.7630Analyst RevisionDAREDaré Bioscience2.2594 of 5 stars$3.18flat$24.00+654.7%-22.7%$27.67M$2.81M-5.3830NAIINatural Alternatives International0.3907 of 5 stars$4.42+3.5%N/A-30.5%$27.40M$113.80M-3.03290Analyst ForecastLGVNLongeveron2.831 of 5 stars$1.85flat$8.00+332.4%-90.3%$26.56M$1.89M-0.2923 Related Companies and Tools Related Companies KALA Competitors RNXT Competitors SRZN Competitors MRKR Competitors PLUR Competitors DRRX Competitors INKT Competitors DARE Competitors NAII Competitors LGVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHE) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDExperts suggest we're on the brink of a major economic shift. Gold's value could soar when Trump brings bac...True Gold Republic | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | SponsoredA huge crack is forming in the US economyFormer Trump Advisor Warning: “An Economic Rupture Is Coming” The legendary financier Brad Thomas served on...Wide Moat Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts